Dr Reddy's launches Obeda oral semaglutide tablets in India

Dr Reddy's Laboratories has launched Obeda, its oral semaglutide product for type 2 diabetes in India, in three daily tablet strengths. The launch makes Dr Reddy's the second Indian company reported to introduce oral semaglutide domestically and follows approval based on an India-based comparative clinical study.

What has Dr Reddy's launched in India?

Dr Reddy's has launched Obeda, an oral semaglutide biosimilar for the treatment of type 2 diabetes in India. The medicine is offered in three tablet strengths and is designed for daily use, adding an oral option to the company's semaglutide portfolio.

Semaglutide is a GLP-1 receptor agonist used in treatments for type 2 diabetes and, in certain formulations and indications, obesity management. The source material identifies Obeda's Indian launch specifically as a type 2 diabetes product. It does not disclose the three individual tablet doses or the product's pricing.

How did Obeda receive regulatory approval?

Dr Reddy's said its oral formulation was clinically evaluated in a head-to-head comparative study conducted in India and was found to be non-inferior to Novo Nordisk's oral semaglutide product, Rybelsus. According to the company spokesperson, this clinical evidence supported approval under India's biosimilar regulatory pathway.

The source material also states that the Central Drugs Standard Control Organisation approved Dr Reddy's to manufacture and sell a generic version of oral semaglutide tablets. This regulatory clearance enabled the company to proceed with its domestic launch plans.

Non-inferiority in a comparative study means the tested medicine met a predefined standard against the reference product rather than demonstrating that it was superior. The company also cited a commitment to reliable supply and consistent quality for Indian patients, although no production or sales projections were disclosed for the oral tablet product.

What is the background to semaglutide competition in India?

The launch follows the expiry of a semaglutide patent in March 2026, according to the source material. Indian pharmaceutical companies have moved to develop and seek approvals for semaglutide products as the molecule has become important in diabetes treatment and weight-management markets globally.

Dr Reddy's had earlier faced limits on domestic semaglutide sales during a patent dispute with Novo Nordisk. The Delhi High Court had allowed the company to manufacture and export its version of semaglutide but restricted domestic sales until March 2026, when Novo Nordisk's secondary patent was due to expire.

The company has also developed semaglutide injections. Dr Reddy's launched a generic semaglutide injection under the Obeda brand in India in March, with 2 mg and 4 mg strengths cited for the once-weekly subcutaneous product. Those injections are distinct from the newly reported daily oral tablet formulation.

What does the launch mean for Dr Reddy's and patients?

For patients, the launch adds another domestically available oral semaglutide option for type 2 diabetes. The availability of three strengths may allow prescribing physicians to use the approved dosing options, though the source does not provide treatment protocols, retail prices, or reimbursement details.

For Dr Reddy's, the launch extends its presence in a therapy area where multiple Indian drugmakers are seeking to introduce semaglutide-based products. The company has said it has sufficient production capacity for its semaglutide plans and intends to work with local partners for the India launch of its injectable product. No revenue contribution or market-share estimate has been provided for Obeda tablets.

The wider market remains shaped by regulatory approvals, the resolution of intellectual-property matters, manufacturing readiness, and the ability to maintain supply. Reports cited in the source material also noted that Dr Reddy's had halted supplies of a semaglutide generic because of an impurity issue before preparing to resume Obeda supplies in India in November. The material does not specify whether that supply update applies to the oral tablets, the injection, or both formulations.

Why is oral semaglutide important for the diabetes market?

Oral semaglutide is significant because it provides a tablet-based formulation of a GLP-1 receptor agonist for type 2 diabetes. Dr Reddy's approval was supported by a direct Indian clinical comparison with the reference oral product, which is a central factual basis for the company's biosimilar regulatory clearance.

The launch also illustrates the growing competitive activity around semaglutide following the March 2026 patent milestone. However, the source does not establish Obeda's price, volume targets, sales outlook, or the number of competing oral products currently available. Those factors will be important in assessing the commercial effect of the launch.

Conclusion

Dr Reddy's has introduced Obeda oral semaglutide tablets for type 2 diabetes in India, with three daily tablet strengths and approval supported by an India-based non-inferiority study against Rybelsus. The product expands Dr Reddy's semaglutide offerings beyond its previously reported injectable formulation and places it among the Indian companies entering this treatment category.

Investors and patients will watch for details on Obeda's supply continuity, pricing, distribution reach, and the pace of competing semaglutide launches. Dr Reddy's has also indicated plans to resume Obeda supplies in India in November and to relaunch the product in Canada in the third quarter, while approvals in other emerging markets remain relevant to its international rollout.